Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | AHCY | P23526 | 2/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25619505 | 1.00 | PNP (0.52) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23474144 | 0.88 | PDE4D (0.68) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL24950975 | 0.88 | PDE4D (0.68) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL24220709 | 0.88 | PDE4D (0.68) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL17752037 | 0.84 | PNP (0.60) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7742864 | 0.82 | PNP (0.63) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL13646020 | 0.82 | PNP (0.63) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL11949491 | 0.82 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL6848324 | 0.82 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7111379 | 0.82 | PNP (0.76) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, TYMP, NTPCR | PNP 8/4885LMNA 3097/4885TP53 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.